Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
Fiche publication
Date publication
juin 2024
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr BOUCHE Olivier, Pr CONROY Thierry, Pr HARLE Alexandre, Dr LAMBERT Aurélien
Tous les auteurs :
Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Abdelghani MB, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf D, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N
Lien Pubmed
Résumé
After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine-based regimens or the modified FOLFIRINOX regimen (mFFX). While mFFX has been shown to be more effective than gemcitabine-based regimens, it is also associated with higher toxicity. Current treatment decisions are based on patient performance status rather than on the molecular characteristics of the tumor. To address this gap, the goal of this study was to develop drug-specific transcriptomic signatures for personalized chemotherapy treatment.
Mots clés
FOLFIRINOX, PRODIGE-24/CCTG PA6 trial, artificial intelligence, gemcitabine, pancreatic cancer, transcriptomic signatures
Référence
Ann Oncol. 2024 06 19;: